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comes in TAVR pts with a failed surgical bioprosthesis who were un-
suitable for open surgery.
METHODS The CoreValve US Expanded Use Study is a prospective, non-
randomized, single arm study that evaluates safety and effectiveness of
TAVR in complex subsets of extreme risk pts including those who are
symptomatic with failed surgical bioprosthesis. Baseline echocardio-
graphic data were reported by the sites, while an independent core lab
evaluated all follow-up ﬁndings. The primary endpoint was a composite
of all-cause mortality or major stroke rate at 1 year.
RESULTS From Mar 2013 – Oct 2014, 143 pts had an attempted
implant. Surgical failure mode was stenosis 59%, regurgitation 24%,
combined 17%. 141/143 (98.6%) pts had successful TAVR implantation
with 2 aborted procedures. Pts were elderly 77  11 years, 66% were
men, STS PROM 9.4  6% and severely symptomatic (NYHA III/IV
87%). All-cause mortality or major stroke at 6 mo was 10.7% (mortality
9%, major stroke 1.8%). 6mo Mod/Sev PVL 1.2% & NYHA III/IV 3.4%.
Permanent pacemaker rate was 8.3%.
CONCLUSIONS CoreValve TAVR in pts with failed surgical bio-
prosthesis at extreme risk for surgery was associated with a low 6 mo
mortality and stroke rate, signiﬁcant reduction in aortic valve gradi-
ents, and a low incidence of moderate/severe PVL and NYHA III/IV
failure.
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BACKGROUND Transcatheter aortic valve replacement has become
the default treatment for patients with severe aortic stenosis at
extreme or high risk for surgery. Extrapolation of the safety and ef-
ﬁcacy established in the CoreValve US Pivotal trials has not been
conﬁrmed after regulatory approval. The objective of this study was to
report the 30-day clinical outcome of patients treated with the Cor-
eValve self-expanding bioprostheses in commercial practice.
METHODS A total of 4913 patients with severe aortic stenosis
implanted with the self-expanding CoreValve at 186 US centers be-
tween January 2014 and March 2015 were included in the Trans-
catheter Valve Therapies (TVT) Registry (extreme risk (ER), 41.5%;
high risk (HR), 53.3%; intermediate risk, 3.6%; other; 1.6%). Patientswere followed for at least 30 days for Valve Academic Research Con-
sortium criteria for mortality and major complications.
RESULTS The 30-day results of the TVT Registry are found in the Table.
A transfemoral approach was used in 89.4% of patients. CoreValve sizing
recommended by CTA included: 23 mm, 4.3%; 26 mm, 22.4%; 29 mm,
38.8%; 31 mm, 34.5%. For discussion, the combined results of the
CoreValve US Pivotal Extreme Risk and High Risk Trials are provided
(Popma JACC 2014, Adams, NEJM 2014) (Table). No statistical
comparisons were performed with the TVT Registry due to the differing
patient populations, data collection and enrollment periods.
CONCLUSIONS This ﬁrst report of the TVT Registry provides assur-
ance of the early safety and effectiveness of the CoreValve self-
expanding bioprosthesis in clinical practice. Longer-term follow-up is
needed to establish the extended beneﬁt in these patients.
TableVariableTVT Registry
N[4,913ER/HR Pivotal Study
N[1,030BaselineAge, years / STS PROM, % 81.1 / 8.8 83.0 / 9.2Diabetes, % / Prior CABG, % 38.4 / 30.1 37.9 / 35.8CAD, % / Prior Pacemaker, % 70.1 / 21.8 79.1 / 24.9Mean AV gradient Pre / Post,
mmHg43.3 / 8.4 48.0 / 9.730-Day EventsAll-cause Mortality, % / Any
Stroke, %5.3 / 2.8 6.9 / 5.0Major Vascular, % / New PPM,
%1.1 / 22.3 7.5 / 20.2Device Thrombosis, % /
Fracture, %0 / 0 0 / 0PVL*, % / Valve-in-Valve, % 9.8 / 3.2 10.5 / 2.6Device Implanted Successfully,
%98.0 98.9CABG ¼ coronary artery bypass surgery; CAD ¼ coronary artery disease; STS PROM¼ STS Predicted Risk of
Mortality; *Moderate or severe.
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BACKGROUND The repositionable CoreValve Evolut R transcatheter
aortic valve (TAV) was designed to permit optimal valve placement at
the desired plane of the native aortic valve and depth of implant. The
Evolut R TAV (26, 29 mm) obtained CE marking after demonstrating
safety and efﬁcacy at 30 days in patients with symptomatic aortic
stenosis and heart-team assessed risk of operative mortality. Out-
comes at 1 year will be available at the time of the meeting.
METHODS The Evolut R CE Study included 60 patients implanted at 6
sites in Australia, New Zealand and the United Kingdom and included
the ﬁrst use of the valve for all operators. An independent echocar-
diographic core laboratory was employed, and Clinical Events Com-
mittee adjudicated major adverse events according to Valve Academic
Research Consortium-2 criteria. Major adverse events, functional
improvement, and valve performance were assessed early post-pro-
cedure, at 30 days, 6 months, and 1 year.
RESULTS A total of 60 patients were enrolled and all received the
Evolut R TAV; mean age was 82.8 6.1 years; 66.7% were women,
68.3% had New York Heart Association (NYHA) III/IV symptoms, and
the mean STS-PROM was 7.0%3.7%. The majority of patients (68.3%)
were considered frail. The repositioning feature of the Evolut R was
successfully used 22 times in 15 patients. There were no deaths at 30
days and all-cause mortality at 6 months was 5.0%. One disabling
stroke occurred between 30-day and 6-month follow-up. There were
no valve embolization, migration, endocarditis or thrombosis events,
and no coronary obstruction. The Evolut R TAV effectively treated the
